73/100B50.330
USD
-0.08
(-0.16%)
Pre Open
Last updated: · Delayed 15 min
Fair value66.10Plus-24%52Price 50.3392
Q4 FY2026 · Earnings report
EPS estimate 0.77Revenue estimate 11.79B
Q4 FY2026 · Earnings report
EPS estimate 0.77Revenue estimate 11.79B
If you had invested in GSK ago, it would be worth $2,056 today, against $4,128 in SPY and $6,186 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
73/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation7.5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
GSK key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Dividend stock · 7.4/10Growth 3.3 · Value 7.1 · Dividend 7.4
- Day range
- 49.000 – 50.725
- 52-week range
- 45.810 – 61.700
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 102.02B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 17.44
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.87
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 2.89
- Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 3.59%
- EPS growth forecast (FY2026)
- +7.1%
- Volume
- 906
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.28
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 64.0/100Environment 54 · Social 65 · Governance 73
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels
- Employees
- 67K
- Website
- gsk.com
- IPO date
- 28 Mar 1980
GSK earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
0.77 USD
Revenue estimate
11.79B USD
Last quarter · Q3 FY2026
EPS1.47Beat +5.0%Revenue11.82BBeat +0.4%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 1.38 | — | — | +11.06% | 11.01B | — | — | +6.85% | |
| Q4 FY2026 | 0.77 | — | — | +13.24% | 11.79B | — | — | +0.13% | |
| Q3 FY2026 | 1.40 | 1.47 | +5.00% | -0.68% | 11.78B | 11.82B | +0.37% | +4.44% | |
| Q2 FY2026 | 1.27 | 1.36 | +7.09% | +10.57% | 11.02B | 11.18B | +1.42% | +5.30% | |
| Q1 FY2026 | 1.16 | 1.24 | +6.90% | +9.73% | 10.23B | 10.30B | +0.69% | +2.60% | |
| Q4 FY2025 | 0.64 | 0.68 | +6.25% | +15.25% | 11.41B | 11.78B | +3.23% | +15.90% | |
| Q3 FY2025 | 1.26 | 1.48 | +17.46% | +16.54% | 11.04B | 11.32B | +2.56% | +8.58% | |
| Q2 FY2025 | 1.12 | 1.23 | +9.82% | +12.84% | 10.50B | 10.61B | +1.12% | +4.81% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 5.29 | — | — | +4.98% | 49.17B | — | — | +3.49% |
| FY2027 | 5.04 | — | — | +4.02% | 47.51B | — | — | +3.92% |
| FY2026 | 4.84 | — | — | +7.12% | 45.72B | — | — | +4.52% |
| FY2025 | 4.53 | 4.52 | -0.21% | +11.88% | 43.56B | 43.75B | +0.43% | +9.62% |
| FY2024 | 3.86 | 4.04 | +4.79% | — | 38.74B | 39.91B | +3.01% | — |
| FY2022 | 3.24 | 3.70 | +14.18% | -5.13% | 35.08B | 38.63B | +10.13% | -9.69% |
| FY2021 | 3.01 | 3.90 | +29.58% | +4.56% | 46.19B | 42.78B | -7.38% | -0.05% |
GSK analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
57.95 USD
+15.14%
Analysts' 1-year price targets range from 55.90 to 60.00, with an average of 57.95.
Past year
1-year forecast
Strong sellStrong buy
Hold
2 ratings
| Buy | 0 | |
| Hold | 1 | |
| Sell | 1 |
12-month price target
| Highest target | 60.00 |
| Average target | 57.95 |
| Lowest target | 55.90 |
| Current price | 50.33 |
GSK valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 17.44
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 10.40
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 2.28
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 4.04
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 11.14
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
102.02B USD
+
Total debt
31.88B USD
−
Cash and short-term investments
3.98B USD
=
Enterprise value
129.92B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
GSK against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Bristol-Myers Squibb, Pfizer, Gilead Sciences, Amgen, Biogen, and Merck & Co., the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median17.43.325.3
- Gross marginHighest in 5 years72.4%66.9%72.4%Against its peers: 3 of 7Peers' median 71.5%
- Operating marginHighest in 5 years25.5%12.8%25.5%Against its peers: 6 of 7Peers' median 28.8%
- Net marginAt its median17.5%8.2%51.0%Against its peers: 4 of 7Peers' median 17.8%
- Return on equityAbove its median35.0%18.8%141.1%Against its peers: 4 of 7Peers' median 36.1%
- Free cash flow marginBelow its median17.8%11.4%23.0%Against its peers: 6 of 7Peers' median 21.5%
- Revenue growthAbove its median4.1%1.4%18.7%Against its peers: 2 of 7Peers' median 1.3%
- EPS growthAbove its median124.2%-67.2%171.1%Against its peers: 2 of 6Peers' median 8.0%
- Debt to EBITDALowest in 5 years1.70×1.70×5.05×Against its peers: 1 of 7Peers' median 2.73×
- Current ratioAt its median0.820.780.91Against its peers: 7 of 7Peers' median 1.40
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
GSK growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 33.47B GBP
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 4.34B GBP
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 72.96%
- Operating margin
- 20.40%
- Net margin
- 12.96%
Revenue / Net income
Revenue Net income Net margin
GSK revenue breakdown
By product
FY2022
100.0%Sub Total
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Sub Total | 8.96B | 100.0% | — |
By region
FY2025
54.7%International45.3%Europe
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| International | 8.28B | 54.7% | — |
| Europe | 6.85B | 45.3% | — |
How GSK makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Revenue32.67B 100.0%
Cost of revenue9.02B 27.6%
Gross profit23.65B 72.4%
Research and development7.53B 23.0%
Selling and administration9.09B 27.8%
Operating income8.34B 25.5%
Tax1.11B 3.4%
Other expense1.51B 4.6%
Net income5.72B 17.5%
FY2025, in GBP. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in GBP. Each band is as wide as its money; the percentage is its share of revenue.
GSK dividendsWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- Annual dividend
- 1.81 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 3.59%
- Payout ratioWhat is the payout ratio? The payout ratio is the share of a company's earnings paid out as dividends: dividends per share divided by earnings per share (EPS).
- 78.58%
- Years of dividend growthWhat are years of dividend growth? The years in a row a company has raised its dividend per share. 25 years make an S&P 500 company a Dividend Aristocrat; 50 make a Dividend King.
- 3
- Frequency
- Quarterly
- Next payment
- 0.45 USD
- Next ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 13 Nov 2026
- Next payment date
- 7 Jan 2027
Dividends per share
GSK financial health
- Cash and short-term investments
- 2.98B GBP
- Total debt
- 23.86B GBP
- Net cash
- -20.88B GBP
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 6.79B GBP
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 0.86
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 1.26
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 8 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 1.81
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
GSK ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 17.30%
- Institutional holders
- 1,080 (+14)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 95.84%
Who owns the shares
Institutions 17.3% Others 82.7%
As of 30 Jun 2026
Shares free to trade
Free float 1.94B shares ·95.8% Closely held 84.36M shares ·4.2%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Title: GSK plc
Sector: Healthcare
Industry: Drug Manufacturers - General
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.